Form 4: Werewolf Therapeutics Director Sells Shares

Luke Evnin, a Director at Werewolf Therapeutics, Inc., reported the sale of 128,185 shares of common stock over three days in early December 2025, pursuant to a pre-established 10b5-1 plan.

Summary

• Director Luke Evnin reported sales of Werewolf Therapeutics, Inc. common stock on December 2, 3, and 4, 2025.
• A total of 128,185 shares were sold across these three days.
• The sales were executed under a Rule 10b5-1 trading plan established on September 24, 2025.
• On December 2, 2025, 38,043 shares were sold at a weighted average price of $0.89, with prices ranging from $0.852 to $0.9246.
• On December 3, 2025, 36,726 shares were sold at a weighted average price of $0.87, with prices ranging from $0.82 to $0.9256.
• On December 4, 2025, 53,416 shares were sold at a weighted average price of $0.97, with prices ranging from $0.92 to $1.0208.
• Following these transactions, the indirect beneficial ownership of common stock decreased to 3,068,278 shares.
• The shares are held indirectly through various MPM entities, and Luke Evnin disclaims beneficial ownership except for his pecuniary interest.

Sentiment

Score: 3

Explanation: The sentiment is mildly negative due to significant insider sales, even though they were pre-planned under a 10b5-1 plan. Sales by a director, especially at relatively low prices, can be interpreted as a lack of strong conviction in the company's short-term stock performance, despite the routine nature of the filing.

Negatives

• A director selling a significant number of shares (128,185 shares) could be perceived negatively by the market, potentially signaling a lack of confidence, even if pre-planned.
• The sales occurred at relatively low prices, ranging from $0.82 to $1.0208 per share.

Future Outlook

NA

Management Comments

• The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

Industry Context

This Form 4 filing is a routine disclosure of insider trading activity and does not provide specific insights into broader industry trends or competitive landscape for the biotechnology sector. Insider sales, even when pre-planned, are often scrutinized by investors for potential signals about a company's near-term prospects, especially in volatile sectors like biotech.

Related Party Transactions

• The shares were sold by and are held through various entities including MPM Asset Management LLC, MPM BioVentures 2014, L.P., MPM BioVentures 2014(B), L.P., MPM Asset Management Investors BV2014 LLC, and MPM Oncology Innovations Fund, L.P. Luke Evnin is a member, Managing Director, or manager of the general partners or managers of these entities.

Stakeholder Impact

• Shareholders may perceive the insider sales as a negative signal, potentially leading to downward pressure on the stock price.
• The transactions do not directly impact employees, customers, suppliers, or creditors.

Key Dates

Recommendation

While the insider sales by Director Luke Evnin are significant in volume and occurred at relatively low prices, they were executed under a pre-established Rule 10b5-1 plan. This mitigates the immediate negative signal somewhat, as the decision to sell was made earlier. However, the sales still represent a reduction in insider exposure. Without additional context on the company's operational performance or strategic outlook, a 'hold' recommendation is appropriate. Investors should monitor future company announcements and financial results to assess the underlying business fundamentals rather than reacting solely to these pre-planned insider sales.

Keywords

Werewolf Therapeutics, HOWL, Luke Evnin, Insider Sales, Form 4, Beneficial Ownership, 10b5-1 Plan, Biotechnology, Pharmaceuticals